Community Trend Report: Retatrutide Interest Up 300% This Month

Fascinating data from our community tracking: Interest in retatrutide has surged 300% over the past 30 days. This triple agonist (GLP-1/GIP/glucagon) is generating serious buzz as we await FDA approval. Why the surge: - Superior weight loss vs semaglutide/tirzepatide in trials - Potential approval timeline becoming clearer - More vendors preparing to stock - Clinical trial data showing 24% average weight loss Source: https://www.nejm.org/ For those tracking this space, retatrutide could be a game-changer when it becomes available. Thoughts on the risk/reward vs established GLP-1s?